



PHARMACY TIMES

BY IEHP PHARMACEUTICAL SERVICES DEPARTMENT
December 21, 2021

IEHP FORMULARY CHANGES AND MEDI-CAL RX UPDATE: November 2021 P&T Update

We would like to inform you of the following changes to the 2021 IEHP Formulary that were approved by the Pharmacy and Therapeutics Subcommittee in November 2021.

AF = Add to Formulary

BOLD = Brand Name

DS = Days' Supply

QL = Quantity Limit

ST = Step Therapy

R-QL = Remove Quantity Limit

AR = Age Restriction

C1 = Code 1 drugs are restricted to certain medical conditions or specific circumstances

PA = Prior Authorization

RF = Remove from Formulary

R-PA = Remove Prior Authorization

R-C1 = Remove Code 1 restriction

NOTE: IEHP is a generic mandated health plan. Brand name drugs are not covered unless indicated or if generic is not available. The FDA recommended maximum dosage limit is applied.

IEHP MEDICARE FORMULARY UPDATES Effective 12/17/2021		
Drug Name	Strength & Dosage Form	Status Change
Alinia (nitazoxanide)	100 mg/5 mL oral suspension	• RF
Aptivus (with vitamin E) (tipranavir)	100 mg/mL oral solution	• RF
Ayvakit (avapritinib)	25 mg tablet 50 mg tablet	• AF • PA (New Starts) • QL= 1/1 DS (25 mg) • QL= 6/1 DS (50 mg)
Banzel (rufinamide)	200 mg tablet 400 mg tablet	• RF
cefuroxime sodium	7.5-gram intravenous solution	• RF

etravirine	100 mg tablet 200 mg tablet	<ul style="list-style-type: none"> • AF • QL= 2/1 DS
guanidine	125 mg tablet	<ul style="list-style-type: none"> • RF
Infanrix (DTaP) (PF)	25 Lf unit-58mcg-10 Lf/0.5mL intramuscular syringe 25 Lf unit-58 mcg-10 Lf/0.5mL intramuscular susp	<ul style="list-style-type: none"> • AF (Syringe) • RF (Suspension)
Ingrezza (valbenazine)	60 mg capsule	<ul style="list-style-type: none"> • AF • PA • QL=1/1 DS
Intelence (etravirine)	100 mg tablet 200 mg tablet	<ul style="list-style-type: none"> • AF • QL=2/1 ds
Kaletra (lopinavir-ritonavir)	100 mg-25 mg tablet 200 mg-50 mg tablet	<ul style="list-style-type: none"> • RF
Kinrix (PF) (Diphtheria and tetanus toxoids, acellular pertussis vaccine)	25 Lf-58 mcg-10 Lf/0.5 mL intramuscular suspension	<ul style="list-style-type: none"> • RF
lithium citrate	8 mEq/5 mL oral solution	<ul style="list-style-type: none"> • RF
lopinavir-ritonavir 200 mg-50 mg tablet	100 mg-25 mg tablet 200 mg-50 mg tablet	<ul style="list-style-type: none"> • AF • QL=8/1 DS (100 mg-25 mg) • QL=4/1 DS (200 mg- 50 mg)
Lumakras (sotorasib)	120 mg tablet	<ul style="list-style-type: none"> • AF • PA (New Starts) • QL=8/1 DS
maprotiline	25 mg tablet 50 mg tablet 75 mg tablet	<ul style="list-style-type: none"> • RF
methyl dopa/hydrochlorothiazide	250 mg-15 mg tablet 250 mg-25 mg tablet	<ul style="list-style-type: none"> • RF
Namenda XR (memantine)	7 mg-14 mg-21 mg-28 mg capsule, sprinkle, ext rel, dose pack	<ul style="list-style-type: none"> • RF
norethindrone-ethinyl estradiol-iron	1 mg-20 mcg (21)-75 mg (7) tablet	<ul style="list-style-type: none"> • AF
Proctosol HC (hydrocortisone)	2.5 % topical cream perineal applicator	<ul style="list-style-type: none"> • RF
propranolol-hydrochlorothiazide 25	40 mg-25 mg tablet 80 mg-25 mg tablet	<ul style="list-style-type: none"> • RF
rufinamide	200 mg tablet 400 mg tablet	<ul style="list-style-type: none"> • AF • PA (New Starts) • QL=8/1 DS
Skyrizi (risankizumab-rzaa)	150 mg/mL subcutaneous pen inj 150 mg/mL subcutaneous syringe	<ul style="list-style-type: none"> • AF • PA
sunitinib	12.5 mg capsule 25 mg capsule 37.5 mg capsule OK 50 mg capsule	<ul style="list-style-type: none"> • AF • PA (New Starts) • QL=4/1 DS (12.5 mg) • QL=2/1 DS (25 mg) • QL=1/1 DS (37.5 mg) • QL=1/1 DS (50 mg)

theophylline ER	450 mg tablet, extended release, 12 hr	<ul style="list-style-type: none"> • AF
TriLyte With Flavor Packets (peg-3350, sodium chloride, sodium bicarbonate and potassium chloride)	420-gram oral solution	<ul style="list-style-type: none"> • RF
Xcopri (cenobamate)	40 mg/week (20 mg x 2) tablet 40 mg twice weekly (80 mg/week) (20 mg x 4) tablet 60 mg/week (20 mg x 3) tablet 80 mg/week (20 mg x 4) tablet 100 mg/week (20 mg x 5) tablet Maintenance Pack 250 mg/day (200 mg x 1 and 50 mg x 1) tablets	<ul style="list-style-type: none"> • RF

Indication, Formulation, and Molecular Entity Updates by Drug	
Drug Name	Updated Information
Botox (onabotulinumtoxinA)	NEW DRUG INDICATION <ul style="list-style-type: none"> • Botox is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for treatment of spasticity in patients 2 years of age and older.
Briivact (brivaracetam)	NEW DRUG INDICATION <ul style="list-style-type: none"> • Briivact is indicated for the treatment of partial-onset seizures in patients 1 month of age and older.
Brukinsa (zanubrutinib)	NEW DRUG INDICATION <ul style="list-style-type: none"> • Brukinsa is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.
Bydureon Bcise (exenatide extended release)	NEW DRUG INDICATION <ul style="list-style-type: none"> • Bydureon Bcise is a glucagon-like peptide-1 receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.
Bylvay (odevixibat)	NEW MOLECULAR ENTITY <ul style="list-style-type: none"> • Bylvay is an ileal bile acid transporter inhibitor indicated for the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis.
Cabometyx (cabozantinib)	NEW DRUG INDICATION <ul style="list-style-type: none"> • Cabometyx is a kinase inhibitor indicated for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible.
Comirnaty (COVID-19 Vaccine, mRNA)	NEW MOLECULAR ENTITY <ul style="list-style-type: none"> • Comirnaty is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 years of age and older.
Drizalma Sprinkle (duloxetine delayed release)	NEW DRUG INDICATION <ul style="list-style-type: none"> • Drizalma Sprinkle is a serotonin and norepinephrine reuptake inhibitor indicated for the treatment of Fibromyalgia in adults.
Erbix (cetuximab)	NEW DRUG INDICATION <ul style="list-style-type: none"> • Erbix is an epidermal growth factor receptor antagonist indicated for treatment of BRAF V600E mutation-positive metastatic colorectal cancer in combination with encorafenib, for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.
Exkivity (mobocertinib)	NEW MOLECULAR ENTITY <ul style="list-style-type: none"> • Exkivity is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor

	exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
FluMist Quadrivalent (influenza vaccine live)	NEW MOLECULAR ENTITY <ul style="list-style-type: none"> FluMist Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.
hydroxychloroquine sulfate	NEW DRUG FORMULATION <ul style="list-style-type: none"> Hydroxychloroquine sulfate is indicated for (1) the treatment of uncomplicated malaria due to <i>P.falciparum</i>, <i>P.malariae</i>, <i>P.ovale</i>, and <i>P.vivax</i> (2) the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported (3) the treatment of chronic discoid lupus erythematosus and systemic lupus erythematosus in adults (4) the treatment of acute and chronic rheumatoid arthritis in adults.
Invega Hafyera (poliperidone palmitate)	NEW DRUG FORMULATION <ul style="list-style-type: none"> extended-release injectable suspension, 1092 mg/3.5 mg, 1560 mg/5 mL
Istodax (romidepsin)	NEW DRUG INDICATION <ul style="list-style-type: none"> Istodax is a histone deacetylase inhibitor indicated for treatment of peripheral T-cell lymphoma in adult patients who have received at least one prior therapy.
Jakafi (ruxolitinib phosphate)	NEW DRUG INDICATION <ul style="list-style-type: none"> Jakafi is a kinase inhibitor indicated for the treatment of chronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
Jardiance (empagliflozin)	NEW DRUG INDICATION <ul style="list-style-type: none"> Jardiance is a sodium-glucose co-transporter 2 inhibitor indicated to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with heart failure and reduced ejection fraction.
Keytruda (pembrolizumab)	NEW DRUG INDICATION <ul style="list-style-type: none"> Keytruda is a programmed death receptor-1-blocking antibody indicated for the treatment of (1) patients with high-risk early-stage Triple Negative Breast Cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery (2) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 [Combined Positive Score (CPS) greater than or equal to 10] as determined by an FDA approved test. Keytruda is a programmed death receptor-1 blocking antibody indicated for renal cell carcinoma (RCC) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC
Lenvima (Lenvatinib)	NEW DRUG INDICATION <ul style="list-style-type: none"> Lenvima is a kinase inhibitor that is indicated in combination with pembrolizumab for the first line treatment of adult patients with advanced renal cell carcinoma (RCC).
Lexette (alobetazol propionate)	NEW DRUG INDICATION <ul style="list-style-type: none"> Lexette is a corticosteroid indicated for the topical treatment of plaque psoriasis in patients twelve years of age and older.
Loreev XR (lorazepam)	NEW DRUG INDICATION <ul style="list-style-type: none"> Loreev XR is indicated for the treatment of anxiety disorders in adults who are receiving stable, evenly divided, three times daily dosing with lorazepam tablets. NEW DRUG FORMULATION <ul style="list-style-type: none"> capsules, extended release, 1 mg, 2 mg, 3 mg
Lybalvi (olanzapine and samidorphan)	NEW MOLECULAR ENTITY <ul style="list-style-type: none"> Lybalvi is a combination of olanzapine, an atypical antipsychotic, and samidorphan, an opioid antagonist, indicated for the treatment of (1) Schizophrenia in adults (2) Bipolar I disorder in adults (a) acute treatment of manic or mixed episodes as monotherapy and as an adjunct to lithium or valproate (b) maintenance monotherapy treatment.

Mirena (levonorgestrel-releasing intrauterine system)	NEW DRUG INDICATION <ul style="list-style-type: none"> Mirena is a progestin-containing intrauterine system indicated for prevention of pregnancy up to 7 years.
Myrbetriq Granules (mirabergron)	NEW DRUG INDICATION <ul style="list-style-type: none"> Myrbetriq is a beta-3 adrenergic agonist indicated for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 years and older and weighing 35 kg or more.
Nexviazyme (avalglucosidase alfa-ngpt)	NEW MOLECULAR ENTITY <ul style="list-style-type: none"> Nexviazyme is a hydrolytic lysosomal glycogen-specific enzyme indicated for the treatment of patients 1 year of age and older with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency).
Nucala (mepolizumab)	NEW DRUG INDICATION <ul style="list-style-type: none"> Nucala is an interleukin-5 antagonist monoclonal antibody (IgG1 kappa) indicated for add-on maintenance treatment of adult patients 18 years and older with chronic rhinosinusitis with nasal polyps (CRSwNP).
Opdivo (nivolumab)	NEW DRUG INDICATION - WITHDRAW <ul style="list-style-type: none"> Opdivo is a programmed death receptor-1-blocking antibody indicated, as a single agent, for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib. NEW DRUG INDICATION <ul style="list-style-type: none"> Opdivo is a programmed death receptor-1 blocking antibody indicated for the adjuvant treatment of patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. NEW DRUG FORMULATION <ul style="list-style-type: none"> injection, 40 mg/4 mL, 100 mg/10 mL, 120 mg/12 mL, 240 mg/24 mL solution in single-dose vials
Opzelura (ruxolitinib)	NEW DRUG FORMULATION <ul style="list-style-type: none"> Opzelura cream is a Janus Kinase (JAK) inhibitor indicated for the short-term, non-continuous topical treatment of mild to moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older whose disease are not adequately controlled by other topical prescription therapies or when those other therapies are not advisable.
Qulipta (atogepant)	NEW MOLECULAR ENTITY <ul style="list-style-type: none"> Qulipta is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of episodic migraine in adults.
Repatha (evolocumab)	NEW DRUG INDICATION <ul style="list-style-type: none"> Repatha is a PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor antibody indicated (1) as an adjunct to diet and other LDL-C lowering therapies in pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C (2) as an adjunct to other LDL-C lowering therapies in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH), to reduce LDL-C.
Rezurock (belumosudil)	NEW MOLECULAR ENTITY <ul style="list-style-type: none"> Rezurock is a kinase inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy.
Saphnelo (anifrolumab-fnia)	NEW MOLECULAR ENTITY <ul style="list-style-type: none"> Saphnelo is a type I interferon receptor antagonist indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus, who are receiving standard therapy.
Semglee (insulin glargine-yfgn)	NEW MOLECULAR ENTITY <ul style="list-style-type: none"> Semglee is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.
Shingrix (zoster vaccine recombinant, adjuvanted)	NEW DRUG INDICATION <ul style="list-style-type: none"> Shingrix is indicated for the prevention of herpes zoster (HZ) in adults aged 18 years and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.

Tasigna (nilotinib hydrochloride)	NEW DRUG INDICATION <ul style="list-style-type: none"> Tasigna is a kinase inhibitor indicated for the treatment of pediatric patients greater than or equal to 1 year of age with PH+ CML-CP and CML-AP resistant or intolerant to prior tyrosine-kinase inhibitor therapy.
Tibsovo (ivosidenib)	NEW DRUG INDICATION <ul style="list-style-type: none"> Tibsovo is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA-approved test with locally advanced or metastatic cholangiocarcinoma who have been previously treated
Tivdak (tisotumab vedotin-tftv)	NEW MOLECULAR ENTITY <ul style="list-style-type: none"> Tivdak is a tissue factor-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
Trudhesa (dihydroergotamine mesylate)	NEW DRUG FORMULATION <ul style="list-style-type: none"> nasal spray, 0.725 mg per spray
Uptravi (selexipag)	NEW DRUG FORMULATION <ul style="list-style-type: none"> injection, 1800 mcg as a lyophilized powder in a single-dose vial
Vaxneuvance (pneumococcal 15-valent conjugate vaccine)	NEW MOLECULAR ENTITY <ul style="list-style-type: none"> Vaxneuvance is a vaccine indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in adults 18 years of age and older.
Xarelto (rivaroxaban)	NEW DRUG INDICATION <ul style="list-style-type: none"> Xarelto is a factor Xa inhibitor indicated to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD.
Xywav (calcium, magnesium, potassium, and sodium oxybates)	NEW DRUG INDICATION <ul style="list-style-type: none"> Xywav is a central nervous system depressant indicated for the treatment of Idiopathic Hypersomnia in adults.

Prior Authorization table available at: www.iehp.org > For Providers > Pharmacy Services > Clinical Information > Prior Authorization Drug Treatment Criteria

For any questions, suggestions, or if you would like a printed copy of the IEHP Formulary Book or Clinical Practice Guideline, please call us at (909) 890-2049. As a reminder, the updated formulary information and Clinical Practice Guidelines are available at www.iehp.org.

Sincerely,
IEHP Pharmaceutical Services